Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Argenx has demonstrated a strong outlook driven by the robust performance of its lead product, Vyvgart, which is experiencing continued growth from the PFS launch, evidenced by a 20% year-over-year increase in new prescribers. The company's recent FDA approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, along with positive Phase 3 results for ocular myasthenia gravis, highlights significant expansion opportunities that could enhance the product's market presence and increase the accessible patient population. Additionally, the successful results from the ADAPT studies reinforce the company's innovative pipeline and bolster confidence in the commercial viability of its therapies, positioning Argenx favorably within the biopharmaceutical landscape.

Bears say

Argenx's outlook reflects significant concerns due to potential delays in obtaining necessary regulatory approvals, which could adversely affect the company's share price. The inherent risks associated with clinical trials pose a threat to the efficacy of argenx’s lead assets and future drug candidates, potentially limiting their market viability. Additionally, the competitive landscape for autoimmune and oncologic diseases is intensifying, as argenx must contend with both established and emerging players offering similar therapeutic options, diminishing its market position.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,027.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,027.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.